Rankings
▼
Calendar
▼
PRLD Q3 2019 Earnings Report — Prelude Therapeutics Incorporated Revenue & Financial Results | Market Cap Arena
Prelude Therapeutics Incorporated
PRLD
Q3 2019 Earnings
Reported September 29, 2019
Quarter Comparison
Revenue
Operating Income
EPS (Diluted)
Free Cash Flow
Metric
Q3 2019
Q2 2019
Q3 2018
QoQ Change
YoY Change
Revenue
$0
—
—
—
—
Op. Income
-$7M
—
—
—
—
EPS (Diluted)
$-0.21
—
—
—
—
Free Cash Flow
-$6M
—
—
—
—
marketcaparena.com
Income Statement
Item
Amount
REVENUE
$0
Cost of Revenue
$0
GROSS PROFIT
$0
R&D Expenses
$5M
Selling & Marketing
$0
General & Administrative
$1M
SG&A Expenses
$1M
Other Expenses
$0
Operating Expenses
$7M
Cost & Expenses
$7M
OPERATING INCOME
-$7M
Interest Income
$0
Interest Expense
$0
Other Income/Expenses
$150.0K
INCOME BEFORE TAX
-$7M
Income Tax Expense
$0
Net Income from Continuing Ops
-$7M
Net Income from Discontinued Ops
$0
Other Adjustments
$0
NET INCOME
-$7M
Net Income Deductions
$0
BOTTOM LINE NET INCOME
-$7M
D&A
$99.0K
EBIT
-$7M
EBITDA
-$7M
EPS
-$0
EPS Diluted
-$0
marketcaparena.com
Cash Flow Statement
Item
Amount
Net Income
-$7M
Depreciation & Amortization
$99.0K
Stock-Based Compensation
$297.0K
Deferred Income Tax
$0
Other Non-Cash Items
$177
Change in Working Capital
$709.0K
OPERATING CASH FLOW
-$6M
Capital Expenditure
-$445.0K
Acquisitions (Net)
$0
Purchases of Investments
$0
Sales/Maturities of Investments
$0
Other Investing Activities
$0
NET CASH FROM INVESTING
-$445.0K
Net Debt Issuance
-$31.0K
Common Stock Repurchased
$0
Common Dividends Paid
$0
Other Financing Activities
$0
NET CASH FROM FINANCING
-$31.0K
FREE CASH FLOW
-$6M
Net Change in Cash
-$6M
marketcaparena.com
← FY 2019
PRLD Overview
Q4 2019 →